This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard W. Light, MD; Elaine J. Merrill; Judy Despars, RN; Geoffrey H. Gordon, MD; Louis R. Mutalipassi, PhD

Arch Intern Med. 1986;146(7):1377-1380.

Abstract
• During each of two six-week treatment periods, 12 depressed outpatients with chronic obstructive pulmonary disease received increasing doses of doxepin hydrochloride or a placebo as tolerated. The mean maximal doses of doxepin hydrochloride and placebo were 105 and 128 mg, respectively. Three of the 12 patients dropped out because of doxepin's side effects. The depression and anxiety scores at the end of the treatment periods were virtually identical and not significantly different from baseline scores. Changes in the 12-minute walking distance were more closely correlated with changes in the depression and anxiety scores than with changes in the forced expiratory volume in 1 s or forced vital capacity. Thus, doxepin is ineffective in treating depressed patients with chronic obstructive pulmonary disease; improvements in the 12-minute walking distance were closely correlated with improvements in the depression or anxiety scores.

(Arch Intern Med 1986;146:1377-1380)

Author Affiliations
From the Departments of Medicine (Drs Light and Gordon and Mss Merrill and Despars) and Psychology (Dr Mutalipassi), Veterans Administration Medical Center, Long Beach, Calif, and the University of California at Irvine (Drs Light and Gordon).

Footnotes
Accepted for publication Oct 15, 1985.

Reprint requests to Pulmonary Disease Section, Veterans Administration Medical Center, Long Beach, CA 90822 (Dr Light).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Depression Care on Outcomes in COPD Patients With Depression
Jordan et al.
Chest 2009;135:626-632.
ABSTRACT | FULL TEXT  

Anxiety and depression in end-stage COPD
Hill et al.
Eur Respir J 2008;31:667-677.
ABSTRACT | FULL TEXT  

Sertraline Effects on Dyspnea in Patients With Obstructive Airways Disease
Smoller et al.
Psychosomatics 1998;39:24-29.
ABSTRACT | FULL TEXT  

Antidepressant therapy in the physically ill: a therapeutic opportunity for the selective 5-HT re-uptake inhibitors?
Lane
J Psychopharmacol 1993;7:112-118.
ABSTRACT